Alkermes (ALKS +1.1%) gets a boost when UBS upgrades shares to a Buy from Neutral. Analyst Ami...

|About: Alkermes plc (ALKS)|By:, SA News Editor

Alkermes (ALKS +1.1%) gets a boost when UBS upgrades shares to a Buy from Neutral. Analyst Ami Fadia sees global sales exceeding $4B by 2016, and sees synergy from the pending buyout of Elan Drug Technologies, a unit of Elan (ELN +2.9%).